XDx is a venture-backed, privately held molecular diagnostics company. XDx’s investors are leaders in life science investing. They bring to XDx extensive strategic, financial, scientific and practical expertise.
Kleiner Perkins Caufield & Byers (KPCB) is an active venture capital partnership headquartered in the San Francisco Bay Area with a large capital base for investment. Since 1972, KPCB has invested in over 525 technology companies (including 85 in biotechnology and medical devices), which have accrued market valuations exceeding $450 billion and employ more than 295,000. In this process, KPCB has been privileged to work with some of America 's most outstanding entrepreneurs, chief executive officers and management teams.
Texas Pacific Group (TPG) is a private equity investment firm founded by David Bonderman, James G. Coulter and William S. Price, III in 1993. The principals of TPG, with affiliated partnerships, have aggregate committed capital of more than $5 billion. TPG's diverse holdings include Oxford Health Plans, Magellan Health Services, Paradyne Networks, Ducati Motor, J. Crew Group, Landis & Gyr Communications and WR Hambrecht + Co. Founded in 2001, Texas Pacific Group Ventures has a total of $500M devoted to investments in information technology and the life sciences in the United States.
The Sprout Group is one of the oldest and largest institutional venture capital firms focused on emerging technology companies. Since its founding in 1969, Sprout Group has financed more than 350 companies and has raised nearly $3.0 billion in committed capital from leading institutional investors and individuals active in the technology industry. In November 2000, Sprout Group closed Sprout IX, a fund totaling $1.1 billion. Sprout Group's investment focus is in communications, software and healthcare technology, industries with rapid long-term growth and significant structural changes. Sprout Group seeks existing or potential market leaders within these sectors and will invest in companies at all stages from start-up through buyout. New Leaf Venture (NLV) Partners is a life science-dedicated venture capital firm with offices in Menlo Park and New York. Founded in 2005 by the former members of Sprout Group's Healthcare Technology venture team, NLV Partners invests primarily in companies focused on clinical-stage biopharmaceutical products, early-stage medical devices and molecular diagnostics. In addition, the NLV Partners team continues to manage the existing $800 million healthcare technology portfolio of Sprout Group.